Publication of new Irinotecan dose banding table 20mg/mL and update Caelyx table

Dear Colleague

NHS England and Improvement has published two new/updated dose banding tables on its website.

• A new irinotecan table has been added to sit alongside the current multi-drug 20mg/mL table to support providers who wish to use the new ready-to-use irinotecan infusion bag products. ‘National Dose Banding Table- Irinotecan 20mgml v.1’ https://www.england.nhs.uk/commissioning/spec-services/npc-crg/group-b/b02/dose-banded-chemotherapy-standardised-product-specifications/
• In addition, NHSE&I have published an updated pegylated-liposomal doxorubicin table, with a change in the name/description to be compliant with most recent MHRA recommendations. ‘National Dose Banding Table – Pegylated-liposomal Doxorubicin (Caelyx®)’ https://www.england.nhs.uk/publication/national-dose-banding-table-doxorubicin-lip-caelyx-2mgml/

BOPA has been informed that there is a document in development that provides assistance with the implementation of the change to licensed ready-to-administer chemotherapy products. ‘Changing to licensed ready-to-administer chemotherapy from unlicensed products or products prepared under section 10 exemption’ This document has been created as a Yellow Cover Document (YCD) and has had the input from technical services and will be published on the specialist pharmacy service website https://www.sps.nhs.uk/ as soon as it is finalised.

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article